Answers are grounded in this paper and cite their sources.
Introduction: There are not enough medicines approved for paediatric use.A very large number of prescriptions are unlicensed or off-label in different countries, diseases and patient ages. Methods:The aim of our retrospective observational study was to analyse the proportion of unlicensed and off-label prescriptions in a paediatric University Hospital Centre (UHC) over a period of six months and to compare this to the alternatives available in the medicines formulary.Results: Of the 1,865 medicines in the formulary, 8.0% were approved for paediatric use without age or weight limit and 47.1% were approved for paediatric use with an age or weight limit.Of the 56,820 prescriptions examined, 30.7% were off-label and 4.5% were unlicensed medicines.53.6% of the 5,803 patients received at least one unlicensed or off-label prescription.This study has enabled us to identify situations (1 to 30 months old, Haematology unit, pantoprazole and folic acid prescription for example), which are more commonly associated with off-label prescribing.Discussion: Our study is original as it examines in parallel those medicines which are available and the prescriptions which are issued.It has analysed a large number of prescriptions for hospitalised patients in sixteen different specialist departments.Off-label or unlicensed prescribing paediatric use raises a safety and efficacy problem for the treatments given.For this reason it is important to target situations and to produce reference standards which can be used in everyday practice by doctors in order to limit their use of these prescriptions.
No takes yet. Share an insight, caveat, or question.
Delmas et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: